Skip to main content

Table 1 Patient characteristics at vedolizumab start

From: Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

Total n (%) 12 (100)
Male n (%) 5 (42)
Type of disease n (%)
Crohn’s disease 7 (58)
Ulcerative colitis 4 (34)
Unclassified inflammatory bowel disease 1 (8)
Age yr, median (range) 15 (8–17)
Disease duration yr, median (range) 2 (1–9)
Previous biologicals n (%)
Infliximab 12 (100)
Adalimumab 11 (92)
Golimumab 1 (8)
Reasons for discontinuation  
Infliximab n (%)  
  Primary non-responder 3 (25)
  Loss of response 7 (58)
  Anaphylactic reaction 2 (17)
Adalimumab n (%)
  Primary non-responder 2 (18)
  Loss of response 7 (64)
  Local allergic reaction 2 (18)
Golimumab n (%)
  Loss of respone 1 (100)